Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform

Tristan M. Sissung; Bevin C. English; David Venzon; William D. Figg; John F. Deeken

doi:10.2217/pgs.09.154

Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform

Tristan M. Sissung, Bevin C. English, David Venzon, William D. Figg, John F. Deeken

Research output: Contribution to journal › Review article › peer-review

67 Scopus citations

Abstract

While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played-and will play - in future pharmacogenetics studies.

Original language	English
Pages (from-to)	89-103
Number of pages	15
Journal	Pharmacogenomics
Volume	11
Issue number	1
DOIs	https://doi.org/10.2217/pgs.09.154
State	Published - 2010
Externally published	Yes

Keywords

DMET
Genome-wide association study
Pharmacogenetics
Pharmacokinetics
Toxicity

Access to Document

10.2217/pgs.09.154

Cite this

@article{6587b4944d8645d3a3e4e5a19fb7d19d,

title = "Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform",

abstract = "While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played-and will play - in future pharmacogenetics studies.",

keywords = "DMET, Genome-wide association study, Pharmacogenetics, Pharmacokinetics, Toxicity",

author = "Sissung, {Tristan M.} and English, {Bevin C.} and David Venzon and Figg, {William D.} and Deeken, {John F.}",

year = "2010",

doi = "10.2217/pgs.09.154",

language = "English",

volume = "11",

pages = "89--103",

journal = "Pharmacogenomics",

issn = "1462-2416",

number = "1",

}

TY - JOUR

T1 - Clinical pharmacology and pharmacogenetics in a genomics era

T2 - The DMET platform

AU - Sissung, Tristan M.

AU - English, Bevin C.

AU - Venzon, David

AU - Figg, William D.

AU - Deeken, John F.

PY - 2010

Y1 - 2010

N2 - While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played-and will play - in future pharmacogenetics studies.

AB - While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played-and will play - in future pharmacogenetics studies.

KW - DMET

KW - Genome-wide association study

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=73549120609&partnerID=8YFLogxK

U2 - 10.2217/pgs.09.154

DO - 10.2217/pgs.09.154

M3 - Review article

C2 - 20017675

AN - SCOPUS:73549120609

SN - 1462-2416

VL - 11

SP - 89

EP - 103

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 1

ER -

Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform

Abstract

Keywords

Access to Document

Fingerprint

Cite this